-+ 0.00%
-+ 0.00%
-+ 0.00%

Syndax Wins Best New Drug Award for Revuforj in Major Cancer Breakthrough

Benzinga·12/12/2025 12:04:34
Listen to the news

Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best New Drug Award recognizes excellence in pharmaceutical development and the drug that represents the best therapeutic advance in its area.

Revuforj is a first-in-class menin inhibitor that was FDA approved in November 2024 for the treatment of relapsed or refractory (R/R) acute leukemia with a KMT2A translocation as determined by an FDA-authorized test in adult and pediatric patients one year and older. In October 2025, Revuforj was approved by the FDA for the treatment of R/R acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options.